Dinan

Researchers are conducting an ambispective, observational, multicenter, and multicohort study focusing on patients with non-small cell lung cancer (NSCLC) who are starting treatment with approved drugs developed by AstraZeneca (AZ) or as part of an AZ alliance. The study includes three groups based on NSCLC stage: resectable, unresectable, and metastatic. This modular study design allows assessment of each new drug indication once it receives European marketing authorization and becomes available in the participating countries. Patients will be enrolled if they have received, are receiving, or will receive approved AZ or AZ alliance drugs either alone or in combination, at any disease stage. Treatment decisions are made by the patients' own doctors before joining the study. The study follows these patients in three cohorts: resectable NSCLC, unresectable NSCLC, and metastatic NSCLC, to evaluate outcomes related to drug effectiveness in real-world settings. Participants will be followed for up to three years to measure outcomes such as disease-free survival, event-free survival, and time to treatment failure, depending on their cohort. Data collection includes retrospective and prospective information on treatment start and patient progress. The study emphasizes real-world evidence by observing patients receiving standard care without intervention from the study team.